Pilot Studies (selection of optimal time points and dosing) In vivo treatment Sample collection (from complex tissue to single cell isolation) Library preparation and sequencing Bioinformatics analysis View our cutting-edge immune profiling and biomarker platforms

Delivering synthetic and medicinal chemistry solutions to global pharma and biotech customers for the discovery of hits, leads, and preclinical candidates. Check out our comprehensive panel of integrated, discovery chemistry services.

Oncology & Immunology Services From the generation and characterization of genetically engineered animal models (GEAMs) to colony management and pre-clinical pharmacology research GEAM generation and characterization Full suite of in vitro testing assays Efficacy, toxicity, and PK/PD services Behavioral assessment platform Large in-house collection of GEAMs (KO/KI, mouse & rat) across multiple therapeutic areas, including: …Read More >

A comprehensive in vitro platform to accelerate cancer immunotherapy drug discovery: Binding & blocking assessment (via biophysical and biochemical assays, and flow cytometry) Immune cell activation (T cell, B cell, and NK cells) Immune cell suppression (MDSC and Treg suppressive assays) Immune T cell polarization and macrophage differentiation Antigen presentation/mixed lymphocyte reaction (including mouse allogenic …Read More >

We offer an extensive panel of inflammatory bowel disease models in mice and rats, including genetically modified, chemically induced, and adoptive transfer-related IBD models. Let our experts help you choose the best IBD animal models to advance your research programs. Learn more about our platform of inflammation models  

Traditional SPR-based drug discovery efforts in the small-molecule space have revolved around single-use chips for screening and hit-to-lead efforts. Inspired by recent technological advances, we have established simple regenerable protocols that can (1) accommodate target-proteins with common tags such as His- and Avi-, (2) reach sufficient surface density for small-molecule testing, and (3) maintain a …Read More >

Macrocyclic peptides are an emerging molecular class for targeting intracellular protein–protein interactions (PPIs) and for providing an oral modality for drug targets. Herein, we use DNA-encoded cyclic peptide libraries to discover a neutral nonapeptide, UNP-6457, that inhibits MDM2–p53 interaction with an IC50 of 8.9 nM. These studies showcase how tailored DEL libraries can directly yield …Read More >

Drug Discovery Chemistry Conference 2023 WuXi AppTec has developed technologies to facilitate RNA small molecule screening, an exciting frontier in drug discovery. SHAPE-MaP is applied to determine RNA structure and dynamics and verify small molecule binding. We utilize the “DNA-Zipper” strategy to enable DNA-encoded libraries to identify RNA binders. With other technologies including fragment-based drug …Read More >

Drug Discovery Chemistry Conference 2023 Powerful biophysical and structural biology tools enable the study of large numbers of covalent fragments and are opening up new possibilities in the treatment of various diseases. Here, Dr. Moran Jerabek-Willemsen, Head of Biophysics & Screening in WuXi Biology reports the results of a covalent FBDD project on Bruton’s Tyrosine …Read More >